Patients with pancreatic cancer (more specifically ductal adenocarcinoma), when detected early can undergo surgical resection of the primary tumour.

Here we report on a clinical trial protocol where, using drug repurposing at the time of surgery, we aim to counteract metastasis-promoting stress and inflammatory reactions. Hence, patients are treated with propranolol and etodolac in the perioperative period.

The study will assess whether this is a safe and feasible procedure while also looking into other biological and clinical endpoints.

Read the full article here.

Learn more about the PROSPER trial here.